Rongbiao Pi

Prof. Rongbiao Pi


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
JCJingkao Chen
Jingkao Chen
ZSZhaowei Sun
Zhaowei Sun
MJMinghua Jin
Minghua Jin
YTYalin Tu
Yalin Tu
SWShengnan Wang
Shengnan Wang
RPRongbiao Pi
Rongbiao Pi

22 July 2019 in Medicinal Research Reviews
Verified
Journal Article
Closed access
LZLili Zhang
Lili Zhang
CCChen Chen
Chen Chen
MMMarvin Sh Mak
Marvin Sh Mak
JLJunfeng Lu
Junfeng Lu
ZWZeqing Wu
Zeqing Wu
RPRongbiao Pi
Rongbiao Pi

23 February 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
RPRongbiao Pi
Rongbiao Pi
XMXuexuan Mao
Xuexuan Mao
XCXiaojuan Chao
Xiaojuan Chao
ZCZhiyi Cheng
Zhiyi Cheng
MLMengfei Liu
Mengfei Liu
YHYifan Han
Yifan Han
We have previously synthesized a series of hybrid compounds by linking ferulic acid to tacrine as multifunctional agents based on the hypotheses that Alzheimer's disease (AD) generates cholinergic deficiency and oxidative stress. Interestingly, we found that they may have potential pharmacological activities for treating AD. Here we report for the first time that tacrine-6-ferulic acid (T6FA), one of these compounds, can prevent amyloid-β peptide (Aβ)-induced AD-associated pathological changes in vitro and in vivo. Our results showed that T6FA significantly inhibited auto- and acetylcholinesterase (AChE)-induced aggregation of Aβ1–40 in vitro and blocked the cell death induced by Aβ1–40 in PC12 cells. In an AD mouse model by the intracerebroventricular injection of Aβ1–40, T6FA significantly improved the cognitive ability along with increasing choline acetyltransferase and superoxide dismutase activity, decreasing AChE activity and malondialdehyde level. Based on our findings, we conclude that T6FA may be a promising multifunctional drug candidate for AD.

5 March 2013 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
MCMeihui Chen
Meihui Chen
ALAnmin Liu
Anmin Liu
YOYing Ouyang
Ying Ouyang
YHYingjuan Huang
Yingjuan Huang
XCXiaojuan Chao
Xiaojuan Chao
RPRongbiao Pi
Rongbiao Pi
Introduction: Rho kinase (ROCK) plays a critical role in actin cytoskeleton organization and is involved in diverse fundamental cellular functions such as contraction and gene expression. Fasudil, a ROCK inhibitor, has been clinically applied since 1995 for the treatment of subarachnoid hemorrhage (SAH) in Japan. Increasing evidences indicate that fasudil could exhibit markedly therapeutic effect on central nervous system (CNS) disorders, such as Alzheimer's disease. Areas covered: This article summarizes results from supporting evidence for the potential therapy for fasudil against a variety of CNS diseases. And the properties of its analogs are also summarized. Expert opinion: Current therapies against CNS disorders are only able to attenuate the symptoms and fail in delaying or preventing disease progression and new approaches with disease-modifying activity are desperately needed. The dramatic effects of fasudil in animal models and/or clinical applications of CNS disorders make it a promising strategy to overcome CNS disorders in human beings. Given the complex pathology of CNS disorders, further efforts are necessary to develop multifunctional fasudil derivatives or combination strategies with other drugs in order to exert more powerful effects with minimized adverse effects in the combat of CNS disorders.

1 February 2018 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
XZXiao Zhang
Xiao Zhang
XHXixin He
Xixin He
QCQiuhe Chen
Qiuhe Chen
JLJunfeng Lu
Junfeng Lu
Simona RapposelliSimona Rapposelli
Simona Rapposelli
RPRongbiao Pi
Rongbiao Pi

1 January 2017 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ZCZiwei Chen
Ziwei Chen
MDMaria Digiacomo
Maria Digiacomo
YTYalin Tu
Yalin Tu
QGQiong Gu
Qiong Gu
SWShengnan Wang
Shengnan Wang
RPRongbiao Pi
Rongbiao Pi